Frankfurt - Delayed Quote EUR

CEL-SCI Corporation (LSRM.F)

0.3478

-0.0004

(-0.11%)

At close: January 10 at 8:05:24 AM GMT+1

CEL-SCI Announces Closing of $5 Million Offering

VIENNA, Va., December 31, 2024--CEL-SCI announces closing of $5 million offering.

Business Wire 12 days ago

CVM
CEL-SCI Announces Pricing of $5 Million Public Offering

VIENNA, Va., December 30, 2024--CEL-SCI announces pricing of $5 million public offering.

Business Wire 13 days ago

CVM
CEL-SCI Announces Proposed Public Offering of Common Stock

VIENNA, Va., December 27, 2024--CEL-SCI announces proposed public offering of common stock.

Business Wire 16 days ago

CVM
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

VIENNA, Va., December 12, 2024--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.

Business Wire last month

CVM
CVM: CRO Selected for Registrational Trial

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the contract research organization (CRO) that will run it and coming to an agreement with the FDA on which biomarkers are appropriate for selecting patients. The view of oncologists as expressed by the

Zacks Small Cap Research last month

CVM
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va., November 07, 2024--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.

Business Wire 2 months ago

CVM
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

VIENNA, Va., October 22, 2024--FDA’s ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.

Business Wire 2 months ago

CVM
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

VIENNA, Va., October 01, 2024--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.

Business Wire 3 months ago

CVM
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

VIENNA, Va., September 16, 2024--CEL-SCI’s Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group.

Business Wire 3 months ago

CVM
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

VIENNA, Va., September 10, 2024--CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 Congress.

Business Wire 4 months ago

CVM
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

VIENNA, Va., September 04, 2024--The UK’s Medicines & Healthcare Products Regulatory Agency grants CEL-SCI a pediatric waiver for Multikine.

Business Wire 4 months ago

CVM
CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reported its fiscal third quarter on August 15, 2024 with the submission of its Form 10-Q with the SEC and a press release on the following day. Since our previous update for the fiscal second quarter, CEL-SCI has added several new individuals to its ranks, conducted a population analysis and

Zacks Small Cap Research 4 months ago

CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

VIENNA, Va., August 15, 2024--CEL-SCI Corporation reports third quarter fiscal 2024 financial results, as well as key recent clinical and corporate developments.

Business Wire 4 months ago

CVM
Cel-Sci: Fiscal Q3 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Wednesday reported a loss of $7.5 million in its fiscal third quarter.

Associated Press Finance 4 months ago

CVM
CEL-SCI Announces Closing of $10.8 Million Offering

VIENNA, Va., July 29, 2024--CEL-SCI announces closing of $10.8 million offering.

Business Wire 5 months ago

CVM
CEL-SCI Announces Pricing of $10.8 Million Offering

VIENNA, Va., July 26, 2024--CEL-SCI announces pricing of $10.8 million offering .

Business Wire 5 months ago

CVM
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

VIENNA, Va., July 26, 2024--CEL-SCI’s phase 3 population analysis for upcoming confirmatory registration study in head & neck cancer demonstrates well balanced patient population

Business Wire 5 months ago

CVM
CEL-SCI Appoints Robert Watson as Chairperson of the Board

VIENNA, Va., July 08, 2024--CEL-SCI appoints Robert Watson as Chairperson of the Board.

Business Wire 6 months ago

CVM
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

VIENNA, Va., June 18, 2024--CEL-SCI Corporation (NYSE American: CVM) today announced the Company’s Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled "Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT" at the International Drug Discovery Science & Technology (IDDST) 20th Annual Congress in Budapest, Hungary on Tuesday, June 18, 2024. Dr. Talor presented during the Cancers/Tumors session which he Chaired along with Dr. Elizabe

Business Wire 6 months ago

CVM
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

VIENNA, Va., June 06, 2024--Dr. Giovanni Selvaggi, who has brought several oncology drugs to market, joins CEL-SCI as Clinical Advisor.

Business Wire 7 months ago

CVM

Performance Overview

Return	LSRM.F	S&P 500
YTD	-7.89%	-1.35%
1-Year	-84.33%	+22.51%
3-Year	-93.68%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CEL-SCI Corporation (LSRM.F)

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

CVM: CRO Selected for Registrational Trial

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Cel-Sci: Fiscal Q3 Earnings Snapshot

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Performance Overview